Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC

April 28th 2025

Treatment with 6.5 mg/kg of tegavivint was associated with primarily grade 1/2 TRAEs in patients with advanced hepatocellular carcinoma.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

CHMP Recommends EU Approval of Zanidatamab for HER2+ Advanced Biliary Tract Cancer

April 25th 2025

The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.

FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Opens the Door to a New Standard Option

April 25th 2025

Jennifer Chan, MD, MPH, highlights the significance of the FDA approval of cabozantinib for the treatment of patients with pNET and epNET.

Awareness Efforts Aim to Drive Earlier Esophageal Cancer Detection Amid Rising Incidence Rates

April 25th 2025

Nataliya Uboha, MD, PhD, highlights the importance of standard endoscopic procedures for the early detection of esophageal cancer.

Companion Diagnostic Nets European IVDR Certification for Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

April 17th 2025

The PD-L1 IHC 22C3 pharmDx assay has been granted European IVDR certification for identifying pembrolizumab eligibility in gastric/GEJ adenocarcinoma.

The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX

April 10th 2025

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC

April 10th 2025

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

IO Research Pays Off in MSI-H/dMMR CRC but Misses the Mark in MSS/pMMR Disease

April 6th 2025

Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs

April 4th 2025

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Dr Chan on the Prevalence of Neuroendocrine Tumors in Young-Adult Patients

April 2nd 2025

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer

April 1st 2025

Tovecimig plus paclitaxel improved overall response rate vs paclitaxel alone in second-line advanced biliary tract cancer.

Tislelizumab Plus Chemo Expands First-Line ESCC Treatment Paradigm

March 31st 2025

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

The OncFive: Top Oncology Articles for the Week of 3/23

March 29th 2025

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Dr Chan on the FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

March 28th 2025

Jennifer Chan, MD, MPH, discusses the FDA approval of cabozantinib for previously treated, advanced well-differentiated (extra) pancreatic neuroendocrine tumors.

FDA Approves Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

March 26th 2025

The FDA has approved cabozantinib (Cabometyx) for use in select patients with pancreatic and extra-pancreatic neuroendocrine tumors.